Avestar Capital’s Pacific Biosciences PACB Stock Holding History

Avestar Capital’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,010	Closed	-$100K	–	374
2022 Q1	$100K	Buy	+11,010	New	+$127K	0.02%	388
2021 Q4	–	Sell	-9,520	Closed	-$243K	–	485
2021 Q3	$243K	Sell	9,520 -1,000	-10%	-$29.6K	0.03%	387
2021 Q2	$368K	Hold	10,520	–	–	0.05%	294
2021 Q1	$354K	Buy	+10,520	New	+$368K	0.08%	223

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Avestar Capital's PACB Position: Q2 2022 in Review

Avestar Capital sold out of Pacific Biosciences (PACB) in Q2 2022, closing a stake of 11,010 shares — an estimated $100K sold.

Avestar Capital first reported a position in PACB in Q1 2021 and held it in 4 quarters. The position peaked at $368K in Q2 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q2 2022.

Avestar Capital reported no remaining Pacific Biosciences position as of Q2 2022 after selling out during the quarter.
Avestar Capital sold 11,010 Pacific Biosciences shares in Q2 2022, an estimated $100K.
Avestar Capital first reported a position in Pacific Biosciences in Q1 2021 and held it in 4 quarters.
Avestar Capital's Pacific Biosciences position peaked at $368K in Q2 2021.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2022.

Based on Avestar Capital's 13F filing for Q2 2022, filed 28 Jul 2022.